Gerda Egger

This study uses advanced human co-culture models to show that fibroblast-derived thrombospondin-1 drives macrophage metabolic remodeling and polarization in tumor environments.

This study establishes a murine tumoroid biobank to identify oncogenic pathways and drug vulnerabilities in prostate cancer, finding that PTEN loss drives cancer pathways and that specific compounds inhibit tumor growth.

This study shows HDAC1 suppresses ALK-positive lymphoma growth, but systemic HDAC inhibition can still be therapeutic.

This study identifies L1TD1's role in promoting LINE-1 retrotransposition by interacting with L1 ORF1p, linking it to cancer progression and early development.

This study investigates how TGF-β affects colorectal cancer tumoroids, finding that aggressive KRAS mutations lead to partial EMT and increased invasiveness.

This study shows that activating GP130 in prostate epithelial cells suppresses tumor growth through senescence and immune activation, suggesting a new therapeutic approach.

This study identifies biomarkers and trajectories of prostate cancer progression using bioinformatics fusion of weighted correlation network analysis and machine learning, finding the EZH2-TROAP axis as a key trajectory and 58 validated biomarkers.